2025
Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve density
2024
Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies
Aggarwal A, Stolear A, Alam M, Vardhan S, Dulgher M, Jang S, Zarich S. Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies. Journal Of Clinical Medicine 2024, 13: 1781. PMID: 38542006, PMCID: PMC10971616, DOI: 10.3390/jcm13061781.Peer-Reviewed Original ResearchCatecholaminergic polymorphic ventricular tachycardiaLeft cardiac sympathetic denervationTraditional first-line treatmentAbsence of structural heart diseaseCalsequestrin 2 geneMyocyte sarcoplasmic reticulumRate of arrhythmic eventsCardiac ryanodine receptorCardiac sympathetic denervationPolymorphic ventricular arrhythmiasFirst-line treatmentPolymorphic ventricular tachycardiaStructural heart diseaseB-blocker therapySudden cardiac deathPotential new therapiesExercise stress testImplantable cardioverter-defibrillatorHereditary arrhythmia syndromesArrhythmia syndromesRyanodine receptorSarcoplasmic reticulumModerate exercise trainingSympathetic denervationArrhythmic events
2023
The Sympathetic Nervous System Promotes Hepatic Lymphangiogenesis, which Is Protective Against Liver Fibrosis
Tanaka M, Jeong J, Thomas C, Zhang X, Zhang P, Saruwatari J, Kondo R, McConnell M, Utsumi T, Iwakiri Y. The Sympathetic Nervous System Promotes Hepatic Lymphangiogenesis, which Is Protective Against Liver Fibrosis. American Journal Of Pathology 2023, 193: 2182-2202. PMID: 37673329, PMCID: PMC10699132, DOI: 10.1016/j.ajpath.2023.08.004.Peer-Reviewed Original ResearchConceptsPartial portal vein ligationNoncirrhotic portal hypertensionCirrhotic patientsVascular endothelial growth factorLiver fibrosisEndothelial growth factorPortal hypertensionSympathetic denervationSympathetic nervesBDL ratsVascular diseaseIdiopathic noncirrhotic portal hypertensionGrowth factorPortal hypertensive patientsPortal vein ligationSympathetic nervous systemMechanisms of lymphangiogenesisCeliac ganglionectomyHypertensive patientsLymphatic vessel numberLiver biopsyLiver cirrhosisVein ligationPPVL ratsHepatic lymphatic vessels
2022
Update on Renal Sympathetic Denervation for the Treatment of Hypertension
Rao A, Krishnan N. Update on Renal Sympathetic Denervation for the Treatment of Hypertension. Current Cardiology Reports 2022, 24: 1261-1271. PMID: 35895182, DOI: 10.1007/s11886-022-01753-x.Peer-Reviewed Original ResearchConceptsRenal sympathetic denervationTreatment of hypertensionRenal sympathetic nervesPathophysiology of hypertensionSympathetic denervationSympathetic nervesBlood pressureSafety of RSDRenal sympathetic nerve fibersAmbulatory blood pressure measurementsAntihypertensive drug useSham-controlled trialAdvanced kidney diseaseSympathetic nerve fibersLong-term efficacyPurpose of ReviewHypertensionBlood pressure measurementsExcellent safety profileModest treatment effectsLong-term safetyAntihypertensive medicationsAldosterone antagonistsCause mortalityNeurogenic controlResistant hypertension
2018
A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer
Borniger J, Walker W, Surbhi, Emmer K, Zhang N, Zalenski A, Muscarella S, Fitzgerald J, Smith A, Braam C, TinKai T, Magalang U, Lustberg M, Nelson R, DeVries A. A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer. Cell Metabolism 2018, 28: 118-129.e5. PMID: 29805100, PMCID: PMC6031468, DOI: 10.1016/j.cmet.2018.04.021.Peer-Reviewed Original ResearchConceptsTumor-bearing miceSleep abnormalitiesMetabolic abnormalitiesIL-6Non-metastatic breast cancerHypocretin/orexin neuronsHypothalamic hypocretin/orexin neuronsPeripheral sympathetic denervationSerum leptin concentrationsTumor-induced increaseTumor-induced changesEnhanced sleep qualityHypocretin/orexinPeripheral inflammationSympathetic denervationExogenous ghrelinOrexin neuronsLeptin concentrationsInterleukin-6Serum glucoseMammary cancerBreast cancerSleep qualityMouse modelCentral neuromodulators
2015
Catecholaminergic Polymorphic Ventricular Tachycardia in Children
Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP, Cohen M, Hamilton RM, Pflaumer A, Kanter RJ, Potts JE, LaPage MJ, Collins KK, Gebauer RA, Temple JD, Batra AS, Erickson C, Miszczak-Knecht M, Kubuš P, Bar-Cohen Y, Kantoch M, Thomas VC, Hessling G, Anderson C, Young ML, Cabrera Ortega M, Lau YR, Johnsrude CL, Fournier A, Kannankeril PJ, Sanatani S. Catecholaminergic Polymorphic Ventricular Tachycardia in Children. Circulation Arrhythmia And Electrophysiology 2015, 8: 633-642. PMID: 25713214, PMCID: PMC4472494, DOI: 10.1161/circep.114.002217.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAnti-Arrhythmia AgentsChildDeath, Sudden, CardiacDefibrillators, ImplantableElectric CountershockFemaleHumansMalePatient SelectionPhenotypeRegistriesRetrospective StudiesRisk FactorsSeverity of Illness IndexSympathectomyTachycardia, VentricularTime FactorsTreatment OutcomeConceptsCatecholaminergic polymorphic ventricular tachycardiaPolymorphic ventricular tachycardiaCardiac sympathetic denervationImplantable cardioverter defibrillatorVentricular tachycardiaSympathetic denervationTreatment failureCardioverter defibrillatorΒ-blockersCatecholaminergic polymorphic ventricular tachycardia patientsQuarter of patientsRetrospective cohort studyDevice-related complicationsTreatment failure eventsYears of ageVentricular tachycardia patientsCohort studyStandard therapySymptom onsetSymptomatic presentationCardiac arrestSubtherapeutic dosingTreatment outcomesElectrical stormTachycardia patients
2014
Renal sympathetic denervation in the treatment of resistant hypertension.
Sánchez-Álvarez C, González-Vélez M, Stilp E, Ward C, Mena-Hurtado C. Renal sympathetic denervation in the treatment of resistant hypertension. The Yale Journal Of Biology And Medicine 2014, 87: 527-35. PMID: 25506285, PMCID: PMC4257026.Peer-Reviewed Original ResearchConceptsTreatment-resistant hypertensionRenal sympathetic denervationSympathetic denervationBlood pressureRenal arteryEfficacy of RSDSYMPLICITY HTN-3 studyDifferent antihypertensive medicationsSympathetic nerve hyperactivityMinor adverse eventsTarget blood pressureCommon femoral arteryMain renal arteryMajor health problemAntihypertensive medicationsRenal denervationRenal sympathectomySymplicity catheterArterial hypertensionResistant hypertensionAdverse eventsConsiderable morbidityEndovascular approachFemoral arteryConcomitant use
2005
Haemodynamic changes induced by hyperbaric bupivacaine during lateral decubitus or supine spinal anaesthesia
Kelly J, McCoy D, Rosenbaum S, Brull S. Haemodynamic changes induced by hyperbaric bupivacaine during lateral decubitus or supine spinal anaesthesia. European Journal Of Anaesthesiology 2005, 22: 717-722. PMID: 16163920, DOI: 10.1017/s0265021505001183.Peer-Reviewed Original ResearchConceptsSystolic blood pressureSpinal anesthesiaBlood pressureMaximum systolic blood pressureMean arterial pressure decreaseSystolic blood pressure decreaseArterial pressure decreaseHyperbaric bupivacaine 0.5Blood pressure decreaseL3-4 interspaceLoss of sensationOnset of hypotensionBlood pressure maintenanceLateral decubitus positionBupivacaine 0.5Hyperbaric bupivacaineIntravenous crystalloidLAT patientsPinprick sensationSmaller total dosesSympathetic denervationIntrathecal injectionArterial pressureHaemodynamic changesHaemodynamic variables
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply